New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine tartrate 3.2 mg/ml equivalent to 2 mg/ml rivastigmine base;   - oral solution - 2 mg/ml - active: rivastigmine tartrate 3.2 mg/ml equivalent to 2 mg/ml rivastigmine base   excipient: citric acid monohydrate purified water quinoline yellow sodium benzoate sodium citrate dihydrate - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - rivastigmine tartrate 2.4mg (rivastigmine hydrogen tartrate equivalent to 1.5 mg rivastigmine); rivastigmine tartrate 2.4mg (rivastigmine hydrogen tartrate equivalent to 1.5 mg rivastigmine) - capsule - 1.5 mg - active: rivastigmine tartrate 2.4mg (rivastigmine hydrogen tartrate equivalent to 1.5 mg rivastigmine) excipient: colloidal silicon dioxide gelatin hypromellose iron oxide yellow magnesium stearate microcrystalline cellulose opacode brown s-1-9460hv purified water sodium laurilsulfate titanium dioxide active: rivastigmine tartrate 2.4mg (rivastigmine hydrogen tartrate equivalent to 1.5 mg rivastigmine) excipient: colloidal silicon dioxide gelatin hypromellose iron oxide yellow magnesium stearate microcrystalline cellulose opacode brown s-1-9460hv opacode red s-1-1666 purified water sodium laurilsulfate titanium dioxide - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - rivastigmine tartrate 4.8mg (rivastigmine hydrogen tartrate equivalent to 3 mg rivastigmine); rivastigmine tartrate 4.8mg (rivastigmine hydrogen tartrate equivalent to 3 mg rivastigmine) - capsule - 3 mg - active: rivastigmine tartrate 4.8mg (rivastigmine hydrogen tartrate equivalent to 3 mg rivastigmine) excipient: colloidal silicon dioxide gelatin hypromellose iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose opacode brown s-1-9460hv purified water sodium laurilsulfate titanium dioxide active: rivastigmine tartrate 4.8mg (rivastigmine hydrogen tartrate equivalent to 3 mg rivastigmine) excipient: colloidal silicon dioxide gelatin hypromellose iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose opacode brown s-1-9460hv opacode red s-1-1666 purified water sodium laurilsulfate titanium dioxide - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - rivastigmine tartrate 7.2mg equivalent to 4.5 mg rivastigmine - capsule - 4.5 mg - active: rivastigmine tartrate 7.2mg equivalent to 4.5 mg rivastigmine excipient: colloidal silicon dioxide gelatin hypromellose iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose opacode white s-1r-7007 purified water sodium laurilsulfate titanium dioxide - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - rivastigmine tartrate 9.6mg (rivastigmine hydrogen tartrate equivalent to 6 mg rivastigmine); rivastigmine tartrate 9.6mg (rivastigmine hydrogen tartrate equivalent to 6 mg rivastigmine) - capsule - 6 mg - active: rivastigmine tartrate 9.6mg (rivastigmine hydrogen tartrate equivalent to 6 mg rivastigmine) excipient: colloidal silicon dioxide gelatin hypromellose iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose opacode brown s-1-9460hv purified water sodium laurilsulfate titanium dioxide active: rivastigmine tartrate 9.6mg (rivastigmine hydrogen tartrate equivalent to 6 mg rivastigmine) excipient: colloidal silicon dioxide gelatin hypromellose iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose opacode brown s-1-9460hv opacode red s-1-1666 purified water sodium laurilsulfate titanium dioxide - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - rivastigmine 13.8mg;   - transdermal patch - 9.5 mg/24h - active: rivastigmine 13.8mg   excipient: colloidal silicon dioxide high molecular weight polyisobutene (adhesive layer) polyethylene/thermoplastic resin/aluminium coated polyester film (backing layer) orange printing ink (release liner) fluoropolymer-coated polyester film (release liner) light liquid paraffin poly(2-ethylhexyl acrylate) vinyl acetate polyisobutylene - treatment of patients with mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease).

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - rivastigmine 6.9mg;   - transdermal patch - 4.6 mg/24h - active: rivastigmine 6.9mg   excipient: colloidal silicon dioxide high molecular weight polyisobutene (adhesive layer) polyethylene/thermoplastic resin/aluminium coated polyester film (backing layer) orange printing ink (release liner) fluoropolymer-coated polyester film (release liner) light liquid paraffin poly(2-ethylhexyl acrylate) vinyl acetate polyisobutylene - treatment of patients with mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease).

European Union - English - EMA (European Medicines Agency)

3m health care limited - rivastigmine - alzheimer disease - psychoanaleptics, , anticholinesterases - symptomatic treatment of mild to moderately severe alzheimer's dementia.

European Union - English - EMA (European Medicines Agency)

krka, d.d. - memantine hydrochloride - alzheimer disease - other anti-dementia drugs - treatment of patients with moderate to severe alzheimer’s disease.

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - memantine hydrochloride - alzheimer disease - other anti-dementia drugs - treatment of patients with moderate to severe alzheimer’s disease.